Calcium channels blockers and progression of kidney disease

Area of Science:

• Nephrology
• Pharmacology
• Internal Medicine

Background:

• Nondiabetic chronic kidney disease (CKD) management often involves agents targeting the renin-angiotensin system.
• Calcium channel blockers (CCBs) are frequently used, but their comparative efficacy in preserving renal function against ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in nondiabetic CKD is debated.

Purpose of the Study:

• To compare the effectiveness of CCB-inclusive regimens versus non-CCB agents (ACEIs and/or ARBs) in slowing disease progression in patients with nondiabetic CKD.

Main Methods:

• Retrospective analysis comparing patient outcomes based on prescribed antihypertensive medication classes.
• Key outcome measures included time to reaching a serum creatinine concentration >7 mg/dL and initiation of dialysis.
• Secondary outcomes assessed included mean serum creatinine levels, rate of creatinine increase, and proteinuria levels.

Main Results:

• No significant difference was observed between CCB and non-CCB groups in reaching end-stage renal disease markers (serum creatinine >7 mg/dL or dialysis initiation).
• Patients treated with CCBs exhibited a higher mean serum creatinine, a faster rate of creatinine increase, and greater proteinuria compared to those on ACEIs/ARBs.
• CCB use and younger age were independently associated with poorer renal function outcomes.

Conclusions:

• CCBs appear less effective than ACEIs or ARBs in preserving renal function and reducing proteinuria in nondiabetic CKD patients.
• These findings suggest that ACEIs or ARBs should be prioritized for renoprotection in this patient population.